Genetic heterogeneity of hepatitis C virus (HCV) in clinical strains of HIV positive and HIV negative patients chronically infected with HCV genotype 3a

Journal of Biological Regulators and Homeostatic Agents

Volumn 17, Issue 2, 2003, Pages 153-161

  Bagaglio, Sabrina ^a   Bruno, R ^b   Lodrini, S ^a   De Mitri, M S ^c   Andreone, P ^c   Loggi, E ^c   Galli, L ^a   Lazzarin, A ^a   Morsica, G ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Hepatitis C; HIV; Hypervariable 1; Interferon; Non structural 5A

Indexed keywords

ALPHA2B INTERFERON; AMINO ACID; ANTIVIRUS AGENT; RIBAVIRIN; VIRUS PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PROTEIN DOMAIN; SEQUENCE ANALYSIS; VIRUS ISOLATION; VIRUS STRAIN;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; OTHER SEQUENCES; RNA VIRUSES; STAPHYLOCOCCUS PHAGE 3A;

EID: 0141728350     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver diseases in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001; 183: 1112-5.
2. McHutchison JG, Gordon SC, Sciff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
3. Causse X, Payen J-L, Babany G, Girardin MF, the French Multicenter Study Group. Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study. J Hepatol 2000; 32: 1003-10.
4. Gale MJ, Korth MJ, Katze MG. Repression of PKR protein kinase by hepatitis C virus NS5A protein: a potential mechanism of interferon resistence. Clin Diagn Virol 1998; 10: 157-62.
5. Gale MJ, Blakely CM, Kwieciszewsky B, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanism of kinase regulation. Mol Cell Biol 1998; 18: 5208-18.
6. Gale MJ, Korth MJ, Tang NM, et al. Evidence that hepatitis C virus resistence to interferon is mediated through repression of PKR protein kinase by nonstructural 5A protein. Virology 1997; 230: 217-27.
7. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in nonstructural 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
8. Sarrazin C, Berg T, Lee JH, et al. Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response. J Infect Dis 2000; 181: 432-41.
9. Sarrazin C, Berg T, Lee JH, et al. Improved correlation between multiple mutations within NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. J Hepatol 1999; 30: 1004-13.
10. Hofgartner WT, Polyak SJ, Sullivan DG, Carithers RL, Gretch DR. Mutations in nonstructural 5A gene of hepatitis C virus in North American patients infected with genotype 1a or 1b. J Med Virol 1997; 53: 118-26.
11. Sarazzin C, Kornetzky I, Ruster B, et al. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. Hepatology 2000; 31: 1360-70.
12. Weiner AJ, Geysen HM, Christopherson C, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infection. PNAS 1992; 89: 3468-72.
13. Del Porto P, Puntoriero G, Scotta C, Nicosia A, Piccolella E. High prevalence of hypervariabile region 1-specific and cross-reactive CD44+7 T cells in HCV-infected individuals responsive to IFN-alpha treatment. Virology 2000; 269: 313-24.
14. Nishiguchi S, Tanaka M, Shiomi S, et al. Changes in hypervariable region 1 in patients with chronic hepatitis C of genotype 1b with biochemical response to interferon. Hepatol Res 2002; 23: 237-50.
15. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTALwindows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997; 25: 4876-82.
16. Felsenstein J. 1993. PHYLIP (Phylogeny Inference Package) version 3.5c. Distributed by the author. Department of Genetics, University of Washington, Seattle, USA.
17. Gerotto M, Sullivan DG, Polyak S J, et al. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. J Virol 1999; 73: 7241-7.
18. Roque-Afonso A M, Robain M, Simoneau D, et al. Influence of CD4 cell counts on the genetic heterogeneity of hepatitis C virus in patients coinfected with human immunodeficiency virus. J Infect Dis 2002; 185: 728-33.